Fierce Biotech Layoff Tracker 2026: Novartis loses 322 US staffers; BioCryst ends internal programs Read more →

AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre Read more →

MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization Read more →